Q9T Stock Overview
A preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ME Therapeutics Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$2.58 |
| 52 Week High | CA$4.14 |
| 52 Week Low | CA$0.61 |
| Beta | 0 |
| 1 Month Change | 21.70% |
| 3 Month Change | -14.00% |
| 1 Year Change | 309.52% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 402.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| Q9T | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 21.7% | 1.2% | -0.3% |
| 1Y | 309.5% | -14.3% | 7.0% |
Return vs Industry: Q9T exceeded the German Biotechs industry which returned -14.3% over the past year.
Return vs Market: Q9T exceeded the German Market which returned 7% over the past year.
Price Volatility
| Q9T volatility | |
|---|---|
| Q9T Average Weekly Movement | 25.7% |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: Q9T's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Q9T's weekly volatility has decreased from 41% to 26% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | n/a | Salim Dhanji | www.metherapeutics.com |
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. Its lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. The company also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations.
ME Therapeutics Holdings Inc. Fundamentals Summary
| Q9T fundamental statistics | |
|---|---|
| Market cap | €47.44m |
| Earnings (TTM) | €0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs Q9T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| Q9T income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €0 |
| Gross Profit | €0 |
| Other Expenses | €0 |
| Earnings | €0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did Q9T perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/26 20:51 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | N/A |
| Annual Earnings | N/A |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ME Therapeutics Holdings Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|